¼¼°èÀÇ ½ÅºÎÀüÁõ ½ÃÀå º¸°í¼­(2025³â)
Renal Insufficiency Global Market Report 2025
»óǰÄÚµå : 1720879
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,344,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,170,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,996,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½ÅºÎÀüÁõ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÀÌ Àü¸ÁµÉ ¿¹Á¤ÀÔ´Ï´Ù. ±Þ¼º ½ÅÀå ¼Õ»ó(AKI)ÀÇ À¯º´·ü Áõ°¡, °¡Á¤ ±â¹Ý Ä¡·á ¿É¼ÇÀÇ Ã¤Åà Áõ°¡, ÀÇ·áºñ ÁöÃâÀÇ ±ÞÁõ, ¿¬±¸°³¹ß ÅõÀÚÀÇ È®´ë µîÀÌ ÀÖ½À´Ï´Ù.

°íÇ÷¾Ð°ú ´ç´¢º´ÀÇ À¯º´·ü »ó½ÂÀº ¾ÕÀ¸·Î ¼ö³â°£ ½ÅºÎÀüÁõ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °íÇ÷¾ÐÀº ÈäÅ͸¦ À¯¹ßÇÏ°í ¿©°ú ´É·ÂÀÇ ÀúÇÏ¿¡ ÀÇÇØ ½ÅÀåÇ÷°ü¿¡ µ¥¹ÌÁö¸¦ ÁÖ°í, ´ç´¢º´Àº Ç÷´çÀÇ »ó½Â¿¡ ÀÇÇØ ½ÅÀå Ç÷°üÀÌ µÎ²¨¿öÁö°í °ú·ÎÇÏ°Ô ¸¸µì´Ï´Ù. 5¿ù ¿µ±¹ Á¤ºÎ±â°üÀÎ ±¹¹Îº¸°Ç¼­ºñ½º(NHS)´Â 2023³â 12¿ù ³²µ¿ºÎÀÇ °íÇ÷¾Ð Áø´Ü ȯÀÚ ¼ö°¡ 7¸¸ 1,120¸í Áõ°¡ÇßÀ¸¸ç 2022³â 12¿ù¿¡ ºñÇØ 5.4% Áõ°¡Çß´Ù°í µ¡ºÙ¿´½À´Ï´Ù. ¿µ±¹À» °ÅÁ¡À¸·Î ÇÏ´Â ÀÚ¼± ´ÜüÀÎ ¿µ±¹ ´ç´¢º´ Çùȸ´Â 2023³â 4¿ù, ¿µ±¹¿¡¼­ 430¸¸¸íÀÌ ´ç´¢º´À̶ó°í Áø´ÜµÇ¾ú´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ±× °á°ú, °íÇ÷¾Ð°ú ´ç´¢º´ÀÇ À¯º´·ü Áõ°¡°¡ ½ÅºÎÀüÁõ ½ÃÀåÀÇ È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

½ÅºÎÀüÁõ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ´ç´¢º´ ¹× ¸¸¼º ½ÅÀ庴(CKD) ȯÀÚÀÇ ½ÅÀå ¹× ½ÉÇ÷°ü ÇÕº´ÁõÀ» ´Ù·ç±â ¶§¹®¿¡ ±Û·çÄ«°ï-À¯»ç ÆéƼµå-1 ¼ö¿ëü ÀÛ¿ëÁ¦(GLP-1 RA)ÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¾àÀº ±Û·çÄÚ¿À½º ÄÁÆ®·ÑÀ» °­È­ÇÏ°í ¿°ÁõÀ» ¾ïÁ¦ÇÏ°í ½ÅÀå¿¡¼­ÀÇ »êÈ­ ½ºÆ®·¹½º¸¦ ÀúÇϽÃÅ´À¸·Î½á ½ÅºÎÀüÁõÀÇ ÁøÇàÀ» Áö¿¬½Ãŵ´Ï´Ù. Nordisk»ç´Â 2Çü ´ç´¢º´°ú CKD¸¦ °¡Áø ¼ºÀο¡¼­ ½ÅÀ庴ÀÇ ÁøÇà, ½ÅºÎÀüÁõ, ½ÉÇ÷°ü»ç À§ÇèÀ» ÁÙÀÌ´Â ¿ÀÁ¨ÇÈ(¼¼¸¶±Û·çƼµå)ÀÇ FDA(½ÄǰÀǾ౹) ½ÂÀÎÀ» ÃëµæÇß½À´Ï´Ù. RAÀÇ ¿ªÇÒÀÌ ³ô¾ÆÁö°í ÀÖÀ½À» °­Á¶ÇÏ´Â °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°, ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Renal insufficiency refers to the decreased ability of the kidneys to filter waste products and maintain fluid and electrolyte balance in the body. It can result from chronic conditions such as diabetes, hypertension, or acute kidney injury, leading to toxin buildup in the blood. If left untreated, renal insufficiency may progress to chronic kidney disease (CKD) or kidney failure, necessitating dialysis or transplantation.

The primary treatment options for renal insufficiency include medications, dialysis, kidney transplantation, and other interventions. Medications help manage symptoms, slow disease progression, and address complications such as high blood pressure, diabetes, and anemia. The condition progresses through different stages, including chronic kidney disease (CKD) stages and end-stage renal disease (ESRD). Treatment is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, with end-users including dialysis centers, hospitals, clinics, and research and academic institutes.

The renal insufficiency market research report is one of a series of new reports from The Business Research Company that provides renal insufficiency market statistics, including renal insufficiency industry global market size, regional shares, competitors with a renal insufficiency market share, detailed renal insufficiency market segments, market trends and opportunities, and any further data you may need to thrive in the renal insufficiency industry. This renal insufficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The renal insufficiency market size has grown rapidly in recent years. It will grow from $10.87 billion in 2024 to $12.14 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth during the historic period can be attributed to the rising cases of high blood pressure and diabetes, the increasing prevalence of chronic kidney disease (CKD), a higher occurrence of urinary tract obstructions, an aging population, and greater awareness and education about kidney health.

The renal insufficiency market size is expected to see rapid growth in the next few years. It will grow to $18.68 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to the rising prevalence of acute kidney injuries (AKI), increasing adoption of home-based treatment options, a surge in healthcare expenditure, and greater investments in research and development. Key trends include advancements in medical technology, innovations in treatment options, the integration of personalized medicine, improvements in dialysis technology, and the development of new and innovative medications.

The rising prevalence of high blood pressure and diabetes is expected to drive the growth of the renal insufficiency market in the coming years. These conditions are influenced by factors such as poor diet, lack of physical activity, obesity, genetic predisposition, and an aging population. High blood pressure damages kidney blood vessels by causing scarring and reducing filtration capacity, while diabetes leads to thickened and overworked kidney vessels due to elevated blood sugar levels. Both conditions accelerate kidney damage, ultimately resulting in renal insufficiency. For example, in May 2024, the National Health Service (NHS), a UK-based government agency, reported that the number of high blood pressure diagnoses in the South East increased by 71,120 patients in December 2023, marking a 5.4% rise compared to December 2022. Additionally, in April 2023, the British Diabetic Association, a UK-based charity organization, stated that 4.3 million people in the UK had been diagnosed with diabetes. Consequently, the increasing prevalence of high blood pressure and diabetes is fueling the expansion of the renal insufficiency market.

Leading companies in the renal insufficiency market are focusing on the development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to address renal and cardiovascular complications in patients with diabetes and chronic kidney disease (CKD). These medications enhance glucose control, reduce inflammation, and lower oxidative stress in the kidneys, thereby slowing the progression of renal insufficiency. For example, in January 2025, Novo Nordisk, a Denmark-based pharmaceutical company, received Food and Drug Administration (FDA) approval for Ozempic (semaglutide) to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD. This approval underscores the growing role of GLP-1 RAs in providing a dual approach to managing diabetes and renal insufficiency, addressing key unmet medical needs for patients with progressive CKD.

In February 2023, AstraZeneca PLC, a UK-based pharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. This acquisition enhances AstraZeneca's cardiorenal portfolio by incorporating baxdrostat (CIN-107), an aldosterone synthase inhibitor designed to lower blood pressure in patients with treatment-resistant hypertension. CinCor Pharma Inc. is a US-based clinical-stage biopharmaceutical company focused on developing treatments for individuals with moderate to severe renal impairment or kidney failure.

Major players in the renal insufficiency market are Kaiser Permanente, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Abbott Laboratories, Medtronic plc, Amgen Inc., Asahi Kasei Medical Co. Ltd., Fujifilm Holdings Corporation, Fresenius Medical Care, Toray Industries Inc., Baxter International Inc., Boehringer Ingelheim, DaVita Inc., Eisai Co. Ltd., Nipro Corporation, Biocon Limited, HemoCue AB, Rockwell Medical, Mitsubishi Tanabe Pharma Corporation, and Sorin Group.

North America was the largest region in the renal insufficiency market in 2024. The regions covered in renal insufficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the renal insufficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The renal insufficiency market consists of sales of dialysis equipment, renal replacement therapies, kidney transplantation services, and pharmaceutical treatments for managing kidney function. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Renal Insufficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on renal insufficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for renal insufficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The renal insufficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Renal Insufficiency Market Characteristics

3. Renal Insufficiency Market Trends And Strategies

4. Renal Insufficiency Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Renal Insufficiency Growth Analysis And Strategic Analysis Framework

6. Renal Insufficiency Market Segmentation

7. Renal Insufficiency Market Regional And Country Analysis

8. Asia-Pacific Renal Insufficiency Market

9. China Renal Insufficiency Market

10. India Renal Insufficiency Market

11. Japan Renal Insufficiency Market

12. Australia Renal Insufficiency Market

13. Indonesia Renal Insufficiency Market

14. South Korea Renal Insufficiency Market

15. Western Europe Renal Insufficiency Market

16. UK Renal Insufficiency Market

17. Germany Renal Insufficiency Market

18. France Renal Insufficiency Market

19. Italy Renal Insufficiency Market

20. Spain Renal Insufficiency Market

21. Eastern Europe Renal Insufficiency Market

22. Russia Renal Insufficiency Market

23. North America Renal Insufficiency Market

24. USA Renal Insufficiency Market

25. Canada Renal Insufficiency Market

26. South America Renal Insufficiency Market

27. Brazil Renal Insufficiency Market

28. Middle East Renal Insufficiency Market

29. Africa Renal Insufficiency Market

30. Renal Insufficiency Market Competitive Landscape And Company Profiles

31. Renal Insufficiency Market Other Major And Innovative Companies

32. Global Renal Insufficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Renal Insufficiency Market

34. Recent Developments In The Renal Insufficiency Market

35. Renal Insufficiency Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â